一品红：子公司获得丙戊酸钠注射用浓溶液注册证书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its sodium valproate injection solution, which is indicated for the treatment of epilepsy in both adults and children when oral formulations cannot be used [1] Group 1: Product Approval - Yipinhong's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the drug registration certificate for sodium valproate injection solution [1] - The approved indication for sodium valproate injection is for the treatment of epilepsy [1] - The mechanism of action for sodium valproate is not fully understood, but it may be related to increasing the concentration of gamma-aminobutyric acid (GABA) in the brain [1]